Perioperative anemia management in colorectal cancer patients: A pragmatic approach

Table 2 Characteristics of the clinical studies examining the role of preoperative iron replacement in colorectal cancer included in this review

Study	Study design	Patients	Baseline Hb (g/dL)	Iron compound dose (mg)	Duration (wk)	Hb (g/dL)	ABT (% or U/pt)
Oral iron
Okuyama et al[46]	OBS	Iron: 32	8.1 ± 1.4	Ferrous citrate	≥ 2	2.0	9.4%
		No iron: 84	8.0 ± 1.6	(200 mg/d)		0.9	27.4%
Lidder et al[47]	RCT	Iron: 23	13.4 ± 1.9	FS	2-8	-0.3	26.0%
		No iron: 22	12.4 ± 2.1	(200 mg TDS)		-0.6	59.0%
Quinn et al[48]	OBS	Iron: 103	12 (10-14)	FS	1-9		0.69 U/pt
		No iron: 167	NS	(200 mg TDS)			1.69 U/pt
Ferrari et al[49]	RCT	FB: 12	11.6 ± 1.6	FB	8	1 (2) mo	NS
				(28-14 mg/d)		0.8 (1.4)
		FS: 12	11.3 ± 1.2	FS		0.7 (1.4)
				(105 mg/d)
Intravenous iron
Edwards et al[57]	RCT	Iron: 34	13.7 ± 0.5	IS	2	-0.2	14.7%
		Placebo: 26	13.4 ± 0.4	(2 × 300 mg)		-0.5	19.2%
Bisbe et al[64]	OBS	IS: 30	10.1 ± 1.2	IS	2-6	0.9	7.0%
				(100-200 mg, 6 ± 3 doses)
		FCM: 15	9.2 ± 1.0	FCM		2.5	40.0%
				(500-1000 mg, 3 ± 1 doses)
Todman et al[68]	Case series	Iron: 22	< 12	Iron isomaltoside-1000	2-6	0.7, 1-2 w	NS
				(20 mg/kg bw)		1.4, 3-4 w
						3.1, 6-8 w

RCT: Randomized controlled trial; OBS: Observational cohort study; Hb: Increment from baseline; ABT: Allogeneic blood transfusion; FB: Ferrous bisglicinate; FS: Ferrous sulphate; IS: Iron sucrose; FCM: Ferric carboxymaltose.